Drug Trial Radar · NCT06673667
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Oct 22, 2024
Primary completion
Apr 23, 2025
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- Kymera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
Conditions
- Healthy Participants Study
Interventions
KT-621Drug
Oral drug
PlaceboDrug
Oral drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically-significant abnormalities in safety laboratory parameters: hematologyTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistryTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulationTime frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (breaths per minute)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
- Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (degrees Celsius)Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Celerion
Phoenix, Arizona
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.